NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...

A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer.

Researchers from National University Hospital (NUH), National Cancer Institute, Singapore (NCIS), the Yong Loo Lin School of Medicine, National University of Singapore, Duke-NUS Medical School and ...

Researchers have found that nanotechnology can increase chemotherapy's effectiveness. The new research could be good news for people who develop peritoneal cancer in the future. "This patient group ...

Peritoneal cancer is difficult to treat and has a poor survival prognosis. But a new and effective nanomedicine delivery system is offering some hope. The company is called NaDeNo and is well underway ...

Treatments for platinum-resistant ovarian cancer are expanding with new FDA-approved immunotherapy combinations and targeted ...